A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response

This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.

Study Overview

• Status: Completed
• Conditions: Hepatitis C, Chronic
• Intervention / Treatment: Drug: Ribavirin; Drug: peginterferon alfa-2a

Detailed Description

During a pre-study run-in phase patients with chronic hepatitis C genotype 2/3, who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care and did not achieve a rapid viral response (RVR) (defined as Hepatitis C virus (HCV) RNA <15 IU/mL at Week 4 of treatment measured with the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test) were eligible for the study and entered the screening phase between treatment Week 4 and 8 as soon as the result of the Week 4 HCV RNA test was available.

Eligible patients entered the study and continued with the dose regimens of PEG-IFN alfa-2a and ribavirin they were taking prior to enrolment into the trial up to Week 24 of treatment. Patients who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24, were randomized at treatment Week 24 to one of the two study groups. Upon randomization, participants either stopped treatment (equaling 24 weeks of treatment) or continued treatment for another 24 weeks (equaling 48 weeks of treatment). A treatment free follow-up period of 24 weeks (for participants in the 48-week treatment group) or 48 weeks (participants in the 24-week treatment group) completed the study.

• Study Type: Interventional
• Enrollment (Actual): 235
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Darlinghurst, Australia, 2010
  • Fremantle, Australia, 6160
  • Melbourne, Australia, 3186
  • Nedlands, Australia, 6009
  • Sydney, Australia, 2139
• Austria
  • Graz, Austria, 8036
  • Innsbruck, Austria, 6020
  • Linz, Austria, 4010
  • Oberndorf, Austria, 5110
  • Wien, Austria, 1160
  • Wien, Austria, 1090
• Belgium
  • Antwerpen, Belgium, 2650
  • Bruxelles, Belgium, 1020
  • Bruxelles, Belgium, 1070
  • Bruxelles, Belgium, 1000
  • Gent, Belgium, 9000
  • Kortrijk, Belgium, 8500
  • Liege, Belgium, 4000
• Brazil
  • Brasilia, Brazil, 70335-000
  • Campinas, Brazil, 13081-970
  • Campinas, Brazil, 13012-970
  • Porto Alegre, Brazil, 90020-090
  • Porto Alegre, Brazil, 90035-003
  • Ribeirao Preto, Brazil, 14049-900
  • Rio de Janeiro, Brazil, 20020-022
  • Santo Andre, Brazil, 09060-650
  • Sao Luis, Brazil, 78048-790
  • Sao Paulo, Brazil, 04040-003
  • Sorocaba, Brazil, 18047-600
  • Vitoria, Brazil, 29043-260
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
  • British Columbia
    • Vancouver, British Columbia, Canada, V6Z 2K5
  • Ontario
    • Hamilton, Ontario, Canada, L8N 4A6
    • Mississauga, Ontario, Canada, L5M 4N4
• Germany
  • Berlin, Germany, 13353
  • Berlin, Germany, 10969
  • Bonn, Germany, 53127
  • Düsseldorf, Germany, 40225
  • Düsseldorf, Germany, 40237
  • Frankfurt Am Main, Germany, 60590
  • Freiburg, Germany, 79106
  • Giessen, Germany, 35392
  • Hamburg, Germany, 20099
  • Heidelberg, Germany, 69120
  • Jena, Germany, 07747
  • Kiel, Germany, 24105
  • Köln, Germany, 50937
  • Mainz, Germany, 55101
  • München, Germany, 81675
  • Offenburg, Germany, 77654
  • Tübingen, Germany, 72076
  • ULM, Germany, 89081
• Mexico
  • Guadalajara, Mexico, 44160
  • Guadalajara, Mexico, 44670
  • Mexicali, Mexico, 21000
  • Mexico City, Mexico, 14050
  • Mexico Df, Mexico, 11649
  • Puebla, Mexico, 72560
• Puerto Rico
  • Santurce, Puerto Rico, 00909
• Switzerland
  • Lausanne, Switzerland, 1005
  • Lugano, Switzerland, 6903
  • St. Gallen, Switzerland, 9007
  • Zürich, Switzerland, 8091
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
  • California
    • La Jolla, California, United States, 92037-1030
    • Lancaster, California, United States, 93534
    • Long Beach, California, United States, 90822
    • Los Angeles, California, United States, 90048
    • Los Angeles, California, United States, 90057
    • Sacramento, California, United States, 95817
    • Sacramento, California, United States, 95816
    • San Diego, California, United States, 92103-8465
    • Torrance, California, United States, 90505
  • Colorado
    • Aurora, Colorado, United States, 80045
  • Florida
    • Jacksonville, Florida, United States, 32256
    • Orlando, Florida, United States, 32803
  • Georgia
    • Atlanta, Georgia, United States, 30308
    • Marietta, Georgia, United States, 30060
  • Hawaii
    • Honolulu, Hawaii, United States, 96813
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70890
    • Opelousas, Louisiana, United States, 70520
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
  • Mississippi
    • Tupelo, Mississippi, United States, 38801
  • Missouri
    • St Louis, Missouri, United States, 63110
    • St Louis, Missouri, United States, 63104
  • New Jersey
    • Egg Harbour Township, New Jersey, United States, 08234
    • Hackensack, New Jersey, United States, 07601
  • New Mexico
    • Albuquerque, New Mexico, United States, 87131
  • New York
    • New York, New York, United States, 10016
    • Syracuse, New York, United States, 13210
  • North Carolina
    • Asheville, North Carolina, United States, 28801
    • Chapel Hill, North Carolina, United States, 27599-7080
    • Winston-salem, North Carolina, United States, 27103
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112-4481
  • Oregon
    • Portland, Oregon, United States, 97239
  • Tennessee
    • Kingsport, Tennessee, United States, 37660
  • Texas
    • Fort Sam Houston, Texas, United States, 78234-3879
  • Utah
    • Salt Lake City, Utah, United States, 84132
  • Virginia
    • Charlottesville, Virginia, United States, 22908
    • Fairfax, Virginia, United States, 22031
    • Richmond, Virginia, United States, 23249

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• adult patients, >=18 years of age;
• serological evidence of chronic hepatitis C (CHC);
• CHC genotype 2 or 3;
• receiving PEGASYS + Copegus according to local standard of care and no rapid viral response (RVR);
• compensated liver disease.

Exclusion Criteria:

• pegylated interferon, standard interferon or ribavirin therapy at any time prior to initiation of current therapy with PEGASYS + Copegus;
• coinfection with hepatitis A or B, or human immunodeficiency virus (HIV);
• history or other evidence of decompensated liver disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PEG-IFN alfa-2a + Ribavirin for 24 weeks; After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.	Drug: Ribavirin; Other Names: Copegus®; Drug: peginterferon alfa-2a; Other Names: Pegasys®; PEG-IFN alfa-2a
Active Comparator: PEG-IFN alfa-2a + Ribavirin for 48 weeks; After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.	Drug: Ribavirin; Other Names: Copegus®; Drug: peginterferon alfa-2a; Other Names: Pegasys®; PEG-IFN alfa-2a

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment	Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period. Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis.	24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment	Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis. Participants without a 24-week post treatment measurement are considered non-responders.	24 weeks after actual end of treatment (range from Week 48 to Week 72).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation	Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA <15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period. Participants without Week 72 measurements were considered non-responders in the analysis.	Week 72
Percentage of Participants With Virological Response at End of Treatment	Virological response at the end of treatment was defined as the percentage of participants with HCV RNA <15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.	End of Treatment (Week 24 and Week 48 for each treatment group respectively).
Percentage of Participants With Virological Relapse	Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment. Virological response at end of treatment is defined as a single last HCV RNA measurement <15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication. Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement <15 IU/ml at least 20 weeks after treatment end.	End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).
Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment	Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis. Participants without a 12-week post treatment measurement are considered non-responders.	12 weeks after actual end of treatment (range from Week 36 to Week 60)
Number of Participants With Adverse Events (AEs)	An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started. A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol. A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity". A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution. This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.	From Week 1 through Week 72.

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: June 1, 2008
• Primary Completion (Actual): May 1, 2012
• Study Completion (Actual): May 1, 2012

Study Registration Dates

• First Submitted: February 18, 2008
• First Submitted That Met QC Criteria: February 18, 2008
• First Posted (Estimate): February 26, 2008

Study Record Updates

• Last Update Posted (Estimate): July 22, 2013
• Last Update Submitted That Met QC Criteria: July 15, 2013
• Last Verified: July 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis; Hepatitis A; Hepatitis C; Hepatitis C, Chronic; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites; Ribavirin; Peginterferon alfa-2a
• Other Study ID Numbers: MV21371; 2007-004993-15